Compare Stocks

→ Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning (From American Hartford Gold Group) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GCTK GlucoTrack	$0.46 -3.5%	$0.38	$0.13 ▼ $0.99	$12.36M	0.29	184,065 shs	202,685 shs
NMTC NeuroOne Medical Technologies	$1.14 -1.7%	$1.17	$0.85 ▼ $2.00	$29.56M	0.81	179,264 shs	27,055 shs
PYPD PolyPid	$4.56 +1.6%	$5.08	$3.57 ▼ $13.50	$21.86M	1.41	3,139 shs	885 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GCTK GlucoTrack	-36.97%	-33.01%	+43.46%	+117.73%	-13.21%
NMTC NeuroOne Medical Technologies	+1.75%	-1.69%	-8.66%	-7.94%	-26.11%
PYPD PolyPid	+0.67%	+1.80%	-4.44%	-30.46%	-65.48%

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GCTK GlucoTrack	0.1724 of 5 stars	0.0	3.0	1.1	2.5	0.0
NMTC NeuroOne Medical Technologies	1.3657 of 5 stars	3.5	5.0	0.6	0.0	0.0
PYPD PolyPid	0.4653 of 5 stars	0.0	5.0	0.6	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GCTK GlucoTrack	N/A	N/A	N/A	N/A
NMTC NeuroOne Medical Technologies	3.00	Buy	$2.20	92.98% Upside
PYPD PolyPid	3.00	Buy	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GCTK GlucoTrack	N/A	N/A	N/A	N/A	$0.15 per share	N/A
NMTC NeuroOne Medical Technologies	$2.82M	10.50	N/A	N/A	$0.26 per share	4.38
PYPD PolyPid	N/A	N/A	N/A	N/A	($1.27) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GCTK GlucoTrack	-$7.10M	-$0.37	N/A	∞	N/A	N/A	-172.38%	-127.42%	5/10/2024 (Estimated)
NMTC NeuroOne Medical Technologies	-$11.86M	-$0.68	N/A	∞	N/A	-478.41%	-267.82%	-200.46%	5/9/2024 (Estimated)
PYPD PolyPid	-$23.86M	-$19.68	N/A	N/A	N/A	N/A	-450.37%	-101.27%	5/8/2024 (Confirmed)

Latest GCTK, NMTC, and PYPD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2024	N/A	PYPD PolyPid	-$1.96	N/A	+$1.96	N/A	N/A	N/A
3/28/2024	Q4 2023	GCTK GlucoTrack	N/A	-$0.10	-$0.10	-$0.10	N/A	N/A
2/14/2024	Q4 2023	PYPD PolyPid	-$2.17	-$3.97	-$1.80	-$3.97	N/A	N/A
2/13/2024	Q1 2024	NMTC NeuroOne Medical Technologies	N/A	-$0.14	-$0.14	-$0.14	N/A	$0.98 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GCTK GlucoTrack	N/A	N/A	N/A	N/A	N/A
NMTC NeuroOne Medical Technologies	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GCTK GlucoTrack	0.06	3.22	3.22
NMTC NeuroOne Medical Technologies	N/A	3.68	2.52
PYPD PolyPid	2.17	0.83	0.83

Ownership

Institutional Ownership

Company	Institutional Ownership
GCTK GlucoTrack	10.92%
NMTC NeuroOne Medical Technologies	16.07%
PYPD PolyPid	26.47%

Insider Ownership

Company	Insider Ownership
GCTK GlucoTrack	17.70%
NMTC NeuroOne Medical Technologies	7.50%
PYPD PolyPid	24.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GCTK GlucoTrack	6	26.76 million	22.02 million	Not Optionable
NMTC NeuroOne Medical Technologies	16	25.93 million	23.99 million	Optionable
PYPD PolyPid	59	4.80 million	3.61 million	No Data

GCTK, NMTC, and PYPD Headlines

Source	Headline
	PYPD: Polypid is Enhancing Surgical Outcomes msn.com - April 24 at 11:46 AM
	PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024 globenewswire.com - April 24 at 7:00 AM
	PolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - April 18 at 12:39 PM
	Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 17.5% americanbankingnews.com - April 15 at 5:58 AM
	PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference globenewswire.com - February 28 at 7:00 AM
	PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock? finance.yahoo.com - February 19 at 6:10 PM
	PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock? zacks.com - February 19 at 1:00 PM
	PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript finance.yahoo.com - February 15 at 11:57 AM
	Buy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market Positioning markets.businessinsider.com - February 14 at 5:44 PM
	PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results finanznachrichten.de - February 14 at 12:44 PM
	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results finance.yahoo.com - February 14 at 7:32 AM
	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results globenewswire.com - February 14 at 7:00 AM
	PolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial finanznachrichten.de - February 12 at 7:54 AM
	PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial finance.yahoo.com - February 12 at 7:54 AM
	PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024 finance.yahoo.com - January 31 at 10:35 AM
	Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session msn.com - January 5 at 3:33 PM
	Cyclacel Pharmaceuticals, Angiodynamic among healthcare movers msn.com - January 5 at 10:29 AM
	PolyPid Ltd. (PYPD) uk.finance.yahoo.com - January 4 at 6:14 PM
	PolyPid looks to raise $16.2M through private placement msn.com - January 4 at 6:14 PM
	PolyPid Announces Private Placement for $16 Million in Gross Proceeds finance.yahoo.com - January 4 at 6:14 PM
	PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 12 at 1:15 PM
	Earnings call: PolyPid's Q3 2023 financial results show decreased expenses and progress in SHIELD II trial investing.com - November 12 at 8:15 AM
	PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results finance.yahoo.com - November 8 at 8:16 AM
	PolyPid's Earnings: A Preview benzinga.com - November 7 at 5:14 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

GlucoTrack

NASDAQ:GCTK

GlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

NeuroOne Medical Technologies

NASDAQ:NMTC

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

PolyPid

NASDAQ:PYPD

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial